The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Exactly - SW has zero value in the SP - that evaporated long ago . So anything postive is positive , no matter how small . Looks like they are using all their skillsets to home in on potential motherlodes - whilst learning huge amounts about the region and further Hav lookalikes . Its what explorers do .
Thanks Troajan . Bexmab news may start attracting some new investors now that there is soon to be a clear and short path to authorisation, but the value in Bexmab is really just the tip of the iceberg . The beauty of Bex is its huge combination potential . The Matins trial has laid the foundation , now we can layer on combi trials in many new areas ( with a Partner or Partners presumably ) . That's where the bigger value is .
I'm hoping that is why Markku has delayed any deal up until now - as he knows the value of Bex is in these further trials , not just an MDS/AML drug ( although that will still be great in itself ).
£3.50 is still in the foothills of value . Plenty more to come .
You can try here -
https://www.voxmarkets.co.uk/rns/announcement/b34cf876-d7bf-440b-8743-fd8f6da3df6c/
Its like feast or famine here that's for sure .
Momentum is building again now though , even if mostly over on the Nas .
Looking forward to what next news is either way .
I've got two other pharma shares on cusps of deals ( AVCT and DEST) .
It would be nice if at least one came good in the next month or so .
Had a little dabble at 1812 - just before it all locked up at the end .
Seemed a bit of severe reaction - for such a big company it sure is a massive move in SP .
Although looking at it's history it does seem pretty volatile .
I feel for holders , days like this are not pleasant .
Anyway , Best of luck .
100k volume on the Nas - and up a further 9% , yet we didn't see Mr 5k taking any from here today .
The ASH conference and the poster has been common knowledge for months .
So I wonder why the sudden interest and surge so late on . Surely it isn't just people just piling in for a punt ?
Like CB says - still 100% owned - so the whole pie is still ours , as will be the glory and future revenues ( at this moment).
Once the FDA give Faron clear direction of how to proceed to market - expect some fireworks .
Looking good this week . News to come soon .
Our session is on Sunday -
https://ash.confex.com/ash/2023/webprogram/Paper174912.html
so perhaps we will get an RNS with latest updated data sets on Bexmab on Monday ?
Just noticed that Faron actually files 2 patents here , not just one .
The first relates to the method on tumours showing Clever 1 expression.
https://patents.google.com/patent/WO2023222953A1/en?assignee=faron+pharmaceuticals&oq=faron+pharmaceuticals&sort=new
A tumor sample which shows substantial percentage of CLEVER-1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.
The second looks very similar but relates to the method on tumours where there is a low PDL1 expression or no PDL1 cells , along with higher percentage of Clever1 expression - suggesting a patient will be receptive .
https://patents.google.com/patent/WO2023222952A1/en?assignee=faron+pharmaceuticals&oq=faron+pharmaceuticals&sort=new
A tumor sample which shows low percentage of PD-L1 expressing cells or not comprising PD-L1 expressing cells together with substantial percentage of CLEVER- 1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.
A small detail - but indicates they are targeting these patients and will all be part of preparations for BEXCOMBO .
16% up over on the Nas - going into the ASH weekend conference - with Markuu excited to reveal the next set of data .
Did anyone else hear Markku talk of the new interim CMO , as someone who knew extensively about the regulatory business of getting accelerated market approvals . Clearly a reason for the switch from MLF I would guess.
I think Nasdaq North was closed yesterday - good to put this out in the lead up to ASH .
interesting interview with the head of ASH this week too - about the importance of new groundbreaking Immunotherapies and targetted treatments for haematological cancers ( ie Bex among others ) .
https://www.youtube.com/watch?v=21erv2hITwE
Https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00501-3
Highlights
•
Targeting Clever-1 with bexmarilimab is well tolerated
•
Disease control in late-stage cancer can be achieved with bexmarilimab monotherapy
•
Low baseline immune activation associates with bexmarilimab benefit
•
Bexmarilimab converts intratumoral macrophages to support adaptive immune responses
New patent also out - detailing the method for patient selection ( in solid tumour situation I'm assuming ).
https://patents.google.com/patent/WO2023222953A1/en?assignee=faron+pharmaceuticals&oq=faron+pharmaceuticals&sort=new
This method requires a sample of the pateint tumour to see if there is any Clever-1 expression . Not read the whole patent yet but it looks like if tumour has a good amount of clever 1 expressing cells , then the patient would liekly respond to the treatment .
A very key element in getting better results and also box ticking for Big Pharma looking to invest .
Another piece of the jigsaw in place .Nice one !
From the blurb
an accurate method has been found for identifying cancer patients that respond to a treatment comprising an administration of an agent capable of binding to CLEVER-1 , preferably anti-CLEVER-1 antibody, more preferably anti- CLEVER-1 antibody bexmarilimab. Especially it has been found an accurate method for pre-treatment identification of cancer patients, which method provides accurate results by machine reading from the stained samples using a specific staining antibody.
Back from a few weeks in the sun to catch up on this very positive interview .
Fully expecting a major partner with resources soon .
Latest data readings look to be as good as expected - coming soon .
Clinical site website also updated - Matins trial now marked as completed - and Bexmab study updated with new US trial sites .
Just need to sit tight now and wait for the good news.
Apologies for my crude attempt at a joke yesterday .
Added again today . I may have missed some of the initial rise , but we are still in the foothills of the real potential SP as Chris build this company up .
I'm comfortable with a longer wait for a deal announcement . He will want to get the best outcome , and there is no need to bite any ones hand off prematurely .
Great update there . Intense discussions , and major relief at cost savings of P2 due to limited numbers allowed by FDA - who seem to be doing all they can to get this drug on the market .
I guess this news wasn't unexpected - but positive all the same , and things look to be gathering pace .
Long way for the SP to climb if and when a deal is done .
I'm not an expert so its just my opinion - but it seems they are running a P2 just on MDS ( which was giving the best data in P1) with existing funds .
I remember Markku answering a question about partners a while back , and he said something along the lines of ' maybe a partner will want to see a P2 before committing'
I'm pretty sure also that you don't start a trial unless you have funding in place to complete it .
I don't think they will fund a P3 alone - but then again their discussions with FDA may throw up some kind of accelerated route .
I believe this is just the start of the news flow .